RxGen, Inc. Signs On As LabCentral Gold Sponsor

  • Provides LabCentral residents and alumni access to preclinical-research team and tools designed to help speed achievement of translational R&D milestones

NEW HAVEN, Conn. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--RxGen, a translational R&D company, and LabCentral, a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups, today announced that RxGen has become a LabCentral Gold sponsor.

“We share LabCentral’s commitment to providing the best possible environment to assure the success of promising therapeutic strategies”

“We are thrilled to welcome RxGen to LabCentral as one of our newest Gold sponsors. Our number one focus is to bring people, ideas, and resources together to assure that the most innovative and promising solutions are advanced efficiently and effectively,” said LabCentral's Co-Founder and President, Johannes Fruehauf, M.D., Ph.D. “A critical ingredient includes access to knowhow and resources within and beyond the walls of LabCentral. By their sponsorship and direct engagement with the LabCentral community, RxGen will bring both.”

“We share LabCentral’s commitment to providing the best possible environment to assure the success of promising therapeutic strategies,” said RxGen CEO, Matthew Lawrence, M.D., Ph.D. “We hope to contribute to that ecosystem by making our scientists, research platform, and unique preclinical research capabilities available to help achieve important milestones early and effectively.”

RxGen’s sponsorship will connect LabCentral scientists and alumni to a translational research team positioned to help propel concepts and candidates to clinical success through early and sustained engagement, and alignment of development strategy with the most predictive possible preclinical modeling and analysis.

About RxGen (www.rx-gen.com)

RxGen is a translational research company devoted to developing and providing predictive preclinical research models to accelerate therapeutic candidate development, and reduce the risk of clinical failure. Formed in 2002, RxGen engages with leading academic, biotechnology, and pharmaceutical sponsors and collaborators to design and execute a wide range of preclinical studies and translational research programs across various therapeutic areas. Application of RxGen’s unique translational capabilities is enabled by flexible scientific and commercial interactions that span contract research services, research collaborations and R&D partnering agreements.

About LabCentral (www.labcentral.org; twitter @labcentral)

A 28,000 square-foot facility in the heart of the Kendall Square, Cambridge, biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for early-stage companies comprising approximately 125 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ? as well as the other critical services and support that startups need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation.

Contacts

MEDIA:
LabCentral:
Caroline A. Grossman, +1-781-771-5579
cgrossman@labcentral.org
or
RxGen:
Christopher Stanley, +1-203-498-9796
info@rx-gen.com

Back to news